Home › Funds › Cadia Private Client LLC › HALO
Cadia Private Client LLC position in HALO
HALOZYME THERAPEUTICS INC · Health Care
Cadia Private Client LLC reported holding 21,500 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.4M, representing 1.64% of its reported portfolio and ranking #16 among its reported holdings. Cadia Private Client LLC has disclosed HALO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Cadia Private Client LLC's HALO position evolved
Cadia Private Client LLC first disclosed a stake in HALO in Q4 2025 at 21,500 shares (US$1.4M). The position peaked in Q3 2026 at 21,500 shares, worth US$2.4M. Across 4 filings, Cadia Private Client LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 21,500 shares valued at US$2.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 21.50K | $1.45M | New |
| Q1 2026 | 21.50K | $1.39M | Hold |
| Q2 2026 | 21.50K | $1.68M | Hold |
| Q3 2026 | 21.50K | $2.37M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- SNYDER CAPITAL MANAGEMENT L P 2.40M sh · $187.54M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.62M sh · $178.46M · Q3 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.58M sh · $174.27M · Q3 2026
- Stephens Investment Management Group LLC 1.41M sh · $156.00M · Q3 2026
- GW&K Investment Management, LLC 1.14M sh · $125.86M · Q3 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- Boston Trust Walden Corp 1.04M sh · $114.35M · Q3 2026
- LMR Partners LLP 45.00M sh · $65.81M · Q2 2026
More on Cadia Private Client LLC
FAQ
How long has Cadia Private Client LLC held HALO?
Cadia Private Client LLC has disclosed HALO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Cadia Private Client LLC's current position in HALO?
As of Q3 2026, Cadia Private Client LLC holds 21.50K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $2.37M, representing 1.64% of its reported portfolio and ranking #16.
Has Cadia Private Client LLC been buying or selling HALO?
In the latest 13F filing (Q3 2026), Cadia Private Client LLC held unchanged its position in HALO. The position peaked in Q3 2026 at 21.50K shares.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.